Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
Twenty-six 8-week-old specific-pathogen-free cats were vaccinated subcutaneously with 2 doses of a commercially available FeLV vaccine, and 26 age-matched specific-pathogen-free cats were similarly vaccinated with a placebo vaccine containing the same adjuvant as the FeLV vaccine. Cats then were randomly assigned to 2 groups of 26 cats (13 FeLV-vaccinated cats and 13 control cats), and each group was housed with 5 cats previously inoculated with FeLV. All cats were tested biweekly for the next 26 weeks for evidence of FeLV antigenemia. Five of the 26 control cats developed antigenemia. However, 4 of these cats were only transiently antigenemic (positive results for 3 consecutive biweekly samples) and only 1 was persistently antigenemic. None of the FeLV-vaccinated cats developed antigenemia. Preventable fraction was calculated to be 100%.
Lafrado
L J
LJ
Department of Veterinary Pathobiology, College of Veterinary Medicine, Ohio State University, Columbus 43210.
D000818:Animals; D000956:Antigens, Viral / Q000097:blood; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D008297:Male; D012192:Retroviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D015682:Retroviridae Proteins, Oncogenic; D016037:Single-Blind Method; D013047:Specific Pathogen-Free Organisms; D014412:Tumor Virus Infections / Q000517:prevention & control / Q000662:veterinary*; D014765:Viral Vaccines
D000956:Antigens, Viral; D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine